Lv0
0 积分 2024-10-29 加入
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
2天前
求助中
Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial
2天前
已完结
Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
2个月前
已关闭
Letter Re: PD-L1 expression associates with favorable survival of patients with cancer of unknown primary (CUP) not treated with checkpoint inhibitors
3个月前
已完结
Beneath the Surface: Novel insights into Amivantamab-induced acneiform rash
3个月前
已完结
Beneath the Surface: Novel insights into Amivantamab-induced acneiform rash
3个月前
已完结
Letter Re: Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed
3个月前
已完结
皖公网安备34019202002308
